Medibio Ltd
ASX:MEB

Watchlist Manager
Medibio Ltd Logo
Medibio Ltd
ASX:MEB
Watchlist
Price: 0.02 AUD Market Closed
Market Cap: 122m AUD

Relative Value

MEB doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of MEB.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MEB Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
126.6
Median 5Y
126.6
Industry
2.3
vs History
vs Industry
Median 3Y
-39.1
Median 5Y
-39.1
Industry
22.5
vs History
vs Industry
Median 3Y
-130.9
Median 5Y
-130.9
Industry
14.4
vs History
vs Industry
Median 3Y
-37.8
Median 5Y
-37.8
Industry
21.4
vs History
vs Industry
Median 3Y
19.4
Median 5Y
19.4
Industry
2.2
vs History
vs Industry
Median 3Y
126.4
Median 5Y
126.4
Industry
2.5
vs History
vs Industry
Median 3Y
126.4
Median 5Y
126.4
Industry
5.2
vs History
vs Industry
Median 3Y
-68.1
Median 5Y
-68.1
Industry
11.9
vs History
vs Industry
Median 3Y
-68.1
Median 5Y
-68.1
Industry
16.8
vs History
vs Industry
Median 3Y
-130.7
Median 5Y
-130.7
Industry
14.5
vs History
vs Industry
Median 3Y
-38.2
Median 5Y
-38.2
Industry
18.6
vs History
vs Industry
Median 3Y
18.9
Median 5Y
18.9
Industry
1.9

Multiples Across Competitors

MEB Competitors Multiples
Medibio Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Medibio Ltd
ASX:MEB
122m AUD 126.6 -39.1 -68.1 -68.1
US
Veeva Systems Inc
NYSE:VEEV
40B USD 13 46.4 35.9 37.5
US
Cerner Corp
LSE:0R00
31.3B USD 5.4 53.1 21.9 43.2
AU
Pro Medicus Ltd
ASX:PME
22.6B AUD 102.3 195.8 135.2 135.2
JP
M3 Inc
TSE:2413
1.5T JPY 4.4 31.8 16.2 19.9
US
Doximity Inc
NYSE:DOCS
8.5B USD 13.7 33.5 29.4 30.8
US
Waystar Holding Corp
NASDAQ:WAY
5.8B USD 5.6 52.2 17.3 27.2
SE
Sectra AB
STO:SECT B
46.6B SEK 20.8 72.1 -142.4 -142.4
IN
Inventurus Knowledge Solutions Ltd
NSE:IKS
283.6B INR 10.6 58.4 36.3 42.4
CN
Winning Health Technology Group Co Ltd
SZSE:300253
21B CNY 9.7 -68.2 -135 -135
US
Inspire Medical Systems Inc
NYSE:INSP
2.9B USD 3.3 64.6 51.8 69.6
P/E Multiple
Earnings Growth PEG
AU
Medibio Ltd
ASX:MEB
Average P/E: 67.5
Negative Multiple: -39.1
N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
46.4
32%
1.5
US
C
Cerner Corp
LSE:0R00
53.1
N/A N/A
AU
Pro Medicus Ltd
ASX:PME
195.8
32%
6.1
JP
M3 Inc
TSE:2413
31.8
16%
2
US
Doximity Inc
NYSE:DOCS
33.5
18%
1.9
US
W
Waystar Holding Corp
NASDAQ:WAY
52.2
N/A N/A
SE
Sectra AB
STO:SECT B
72.1
17%
4.2
IN
I
Inventurus Knowledge Solutions Ltd
NSE:IKS
58.4
31%
1.9
CN
Winning Health Technology Group Co Ltd
SZSE:300253
Negative Multiple: -68.2
92%
N/A
US
Inspire Medical Systems Inc
NYSE:INSP
64.6
13%
5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Medibio Ltd
ASX:MEB
Average EV/EBITDA: 43
Negative Multiple: -68.1
N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
35.9
39%
0.9
US
C
Cerner Corp
LSE:0R00
21.9
N/A N/A
AU
Pro Medicus Ltd
ASX:PME
135.2
32%
4.2
JP
M3 Inc
TSE:2413
16.2
14%
1.2
US
Doximity Inc
NYSE:DOCS
29.4
23%
1.3
US
W
Waystar Holding Corp
NASDAQ:WAY
17.3
24%
0.7
SE
Sectra AB
STO:SECT B
Negative Multiple: -142.4 N/A N/A
IN
I
Inventurus Knowledge Solutions Ltd
NSE:IKS
36.3
24%
1.5
CN
Winning Health Technology Group Co Ltd
SZSE:300253
Negative Multiple: -135
36%
N/A
US
Inspire Medical Systems Inc
NYSE:INSP
51.8
85%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Medibio Ltd
ASX:MEB
Average EV/EBIT: 50.7
Negative Multiple: -68.1
N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
37.5
39%
1
US
C
Cerner Corp
LSE:0R00
43.2
N/A N/A
AU
Pro Medicus Ltd
ASX:PME
135.2
31%
4.4
JP
M3 Inc
TSE:2413
19.9
N/A N/A
US
Doximity Inc
NYSE:DOCS
30.8
25%
1.2
US
W
Waystar Holding Corp
NASDAQ:WAY
27.2
58%
0.5
SE
Sectra AB
STO:SECT B
Negative Multiple: -142.4 N/A N/A
IN
I
Inventurus Knowledge Solutions Ltd
NSE:IKS
42.4
26%
1.6
CN
Winning Health Technology Group Co Ltd
SZSE:300253
Negative Multiple: -135
47%
N/A
US
Inspire Medical Systems Inc
NYSE:INSP
69.6
34%
2